263 related articles for article (PubMed ID: 29027246)
21. Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity.
El Newahie AM; Ismail NS; Abou El Ella DA; Abouzid KA
Arch Pharm (Weinheim); 2016 May; 349(5):309-26. PubMed ID: 27062086
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of aurora kinases inhibitors based on N-trisubstituted pyrimidine scaffold.
Long L; Luo Y; Hou ZJ; Ma HJ; Long ZJ; Tu ZC; Huang LJ; Liu Q; Lu G
Eur J Med Chem; 2018 Feb; 145():805-812. PubMed ID: 29358147
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres.
Jorda R; Paruch K; Krystof V
Curr Pharm Des; 2012; 18(20):2974-80. PubMed ID: 22571665
[TBL] [Abstract][Full Text] [Related]
24. Single step synthesis of new fused pyrimidine derivatives and their evaluation as potent Aurora-A kinase inhibitors.
Shaaban MR; Saleh TS; Mayhoub AS; Farag AM
Eur J Med Chem; 2011 Sep; 46(9):3690-5. PubMed ID: 21664013
[TBL] [Abstract][Full Text] [Related]
25. A Review on Anticancer Activities of Thiophene and Its Analogs.
Mishra R; Kumar N; Mishra I; Sachan N
Mini Rev Med Chem; 2020; 20(19):1944-1965. PubMed ID: 32669077
[TBL] [Abstract][Full Text] [Related]
26. Discovery of 2-arylamino-4-(1-methyl-3-isopropylsulfonyl-4-pyrazol-amino)pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Jin C; Meng X; Sun D; Xu X; Zhou Y; Liang Z; Ji M; Li H; Xu T; Song G; Zhang L; Chen G; Yuan H; Shih J; Zhang R; Hou G; Jin Y; Yang Q
Bioorg Med Chem Lett; 2015 Sep; 25(17):3738-43. PubMed ID: 26130408
[TBL] [Abstract][Full Text] [Related]
27. Application and SARs of Pyrazolo[1,5-a]pyrimidine as Antitumor Agents Scaffold.
Zhang Y; Wen D; Shen J; Tian L; Zhu Y; Zhang J; Zhao L; Ding S; Liu J; Chen Y
Curr Top Med Chem; 2023; 23(12):1043-1064. PubMed ID: 36852801
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and bioevaluation study of novel N-methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitors.
Wang L; Xu S; Chen X; Liu X; Duan Y; Kong D; Zhao D; Zheng P; Tang Q; Zhu W
Bioorg Med Chem; 2018 Jan; 26(1):245-256. PubMed ID: 29203143
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
30. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.
Sleebs BE; Nikolakopoulos G; Street IP; Falk H; Baell JB
Bioorg Med Chem Lett; 2011 Oct; 21(19):5992-4. PubMed ID: 21852129
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.
Tang Q; Zhang G; Du X; Zhu W; Li R; Lin H; Li P; Cheng M; Gong P; Zhao Y
Bioorg Med Chem; 2014 Feb; 22(4):1236-49. PubMed ID: 24485123
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
Zhao Y; Zhang J; Zhuang R; He R; Xi J; Pan X; Shao Y; Pan J; Sun J; Cai Z; Liu S; Huang W; Lv X
Bioorg Med Chem; 2017 Jun; 25(12):3195-3205. PubMed ID: 28412159
[TBL] [Abstract][Full Text] [Related]
33. Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
Salerno S; Marini AM; Fornaciari G; Simorini F; La Motta C; Taliani S; Sartini S; Da Settimo F; García-Argáez AN; Gia O; Cosconati S; Novellino E; D'Ocon P; Fioravanti A; Orlandi P; Bocci G; Dalla Via L
Eur J Med Chem; 2015 Oct; 103():29-43. PubMed ID: 26318056
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
[TBL] [Abstract][Full Text] [Related]
35. 2-Anilino-4-(benzimidazol-2-yl)pyrimidines--a multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines.
Determann R; Dreher J; Baumann K; Preu L; Jones PG; Totzke F; Schächtele C; Kubbutat MH; Kunick C
Eur J Med Chem; 2012 Jul; 53():254-63. PubMed ID: 22560627
[TBL] [Abstract][Full Text] [Related]
36. Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors.
Munikrishnappa CS; Puranik SB; Kumar GV; Prasad YR
Eur J Med Chem; 2016 Aug; 119():70-82. PubMed ID: 27155464
[TBL] [Abstract][Full Text] [Related]
37. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors.
Luo Y; Deng YQ; Wang J; Long ZJ; Tu ZC; Peng W; Zhang JQ; Liu Q; Lu G
Eur J Med Chem; 2014 May; 78():65-71. PubMed ID: 24681066
[TBL] [Abstract][Full Text] [Related]
39. Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Das D; Hong J
Eur J Med Chem; 2019 May; 170():55-72. PubMed ID: 30878832
[TBL] [Abstract][Full Text] [Related]
40. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S
Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
